The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lower the CAD risk, the higher the chance of a false positive”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [248]
In the citing paper
“During the entire follow-up period, the rate of death among patients in the conventionaltherapy group was 50%, a finding that underscores the poor prognosis for such patients in the absence of intensive treatment.20”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [20]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,094
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Cardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163 · cited 1×
“Previous models for CHD, such as the Framingham risk equations [20, 21 ], have not been specifically designed for people with Type II diabetes.”
MethodModelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
Self-citation(2000) · PubMed · Cited by 2,095
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Prevention of coronary heart disease in clinical practice
PYÖRÄLÄ, K., BACKER, G. D., GRAHAM, I., POOLE-WILSON, P., & WOOD, D. (1994) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a060388 · Cited by 1,163
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,021
Khaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017 · cited 1×
“The importance of HbA "c as a continuous risk factor for CHD, in Type II diabetes, is underlined by the results of Table 4. A causal relationship between glycaemia, measured by HbA "c , and CHD has not been proved [16], but a predictive relationship has been established [18, 45 ].”
BackgroundManson, J. E. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.6.1141 · Cited by 675
Grundy, S. M., Balady, G. J., Criqui, M. H., Fletcher, G., Greenland, P., Hiratzka, L. F., Houston-Miller, N., Kris-Etherton, P., Krumholz, H. M., LaRosa, J., et al. (1998) · Circulation · doi:10.1161/01.cir.97.18.1876 · Cited by 609
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
Koskinen, P., Mänttäri, M., Manninen, V., Huttunen, J. K., Heinonen, O. P., & Frick, M. H. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.820 · Cited by 509
Barrett-Connor, E. L. (1991) · JAMA · doi:10.1001/jama.1991.03460050081025 · Cited by 413
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Copley-Merriman, C., Maier, W., Dong, F., Manninen, D., Zbrozek, A. S., Kotsanos, J., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.735 · Cited by 333
Correcting for Regression Dilution Bias: Comparison of Methods for a Single Predictor Variable
Frost, C., & Thompson, S. G. (2000) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/1467-985x.00164 · Cited by 314 · cited 2×
“Since HbA "c , blood pressure and lipid measurements are all subject to within-person variation, users of the model should consider the effect of regression dilution on estimates [ 51 ].”
BackgroundMethodStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · Cited by 302
Model of Complications of NIDDM: I. Model construction and assumptions
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Zbrozek, A. S., Dong, F., Manninen, D., Garfield, S. A., Copley-Merriman, C., Maier, W., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.725 · Cited by 258
Assmann, G., Cullen, P., Jossa, F., Lewis, B., & Mancini, M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.8.1819 · Cited by 227
Ramsay, L., Haq, I., Jackson, P., Yeo, W., Pickin, D., & Payne, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05516-x · Cited by 168
Grover, S. A., Paquet, S., Levinton, C. M., Coupal, L., & Zowall, H. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.655 · Cited by 155
Silent Myocardial Ischemia and Infarction: Insights from the Framingham Study
Kannel, W. B. (1986) · Cardiology Clinics · doi:10.1016/s0733-8651(18)30577-0 · Cited by 128
Regression Dilution in the Proportional Hazards Model
Hughes, M. D. (1993) · Biometrics · doi:10.2307/2532247 · Cited by 114
Using the Framingham model to predict heart disease in the United Kingdom: retrospective study
Ramachandran, S., French, J. M., Vanderpump, M. P., Croft, P., & Neary, R. H. (2000) · BMJ · doi:10.1136/bmj.320.7236.676 · Cited by 112
The global diabetes model: user friendly version 3.0
Brown, J. B., Russell, A., Chan, W., Pedula, K. L., & Aickin, M. G. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00215-1 · Cited by 108
Clarke, P., Gray, A., Adler, A., Stevens, R., Raikou, M., Cull, C., Stratton, I., & Holman, R. (2001) · Diabetologia · doi:10.1007/s001250051617 · Cited by 99
Self-citationManley, S. E., Meyer, L., Neil, H., Ross, I. S., Turner, R. C., & Holman, R. R. (1994) · Diabetic Medicine · Cited by 86
Airaksinen, J. K. E. (2001) · Diabetologia · doi:10.1007/s001250051609 · Cited by 84 · cited 1×
“Some authors have suggested that the increased prevalence of silent MI in diabetes is in proportion to the increase in CHD [ 48 ], though evidence from the Framingham study suggests that this may vary with sex [49].”
BackgroundCost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes
Grover, S. A., Coupal, L., Zowall, H., & Dorais, M. (2000) · Circulation · doi:10.1161/01.cir.102.7.722 · Cited by 68
The Mt. Hood challenge: cross-testing two diabetes simulation models
Brown, J. B., Palmer, A. J., Bisgaard, P., Chan, W., Pedula, K. L., & Russell, A. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00217-5 · Cited by 65 · cited 3×
“the Institute for Medical Informatics and Biostatistics (IMIB) diabetes model and the Global Diabetes Model (GDM) [ 15 ].”
MethodInfluentialApproach to maintaining comparability of biochemical data during long-term clinical trials
Cull, C. A., Manley, S. E., STRATTON, I. M., Neil, H. A. W., Ross, I. S., Holman, R. R., Turner, R. C., & Matthews, D. R. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.10.1913 · Cited by 28
Self-citationLife-expectancy projection by modelling and computer simulation (UKPDS 46)
Stevens, R., Adler, A., Gray, A. M., Briggs, A. H., & Holman, R. R. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00214-x · Cited by 22 · cited 1×
“Using a previously published simple life-expectancy model, this reduces the 20-year risk of CHD from 33 % to 29 % [ 50 ].”
MethodSelf-citationFeher, M. D., & Elkeles, R. S. (1999) · Heart · doi:10.1136/hrt.81.1.10 · Cited by 16
Packard, C. J., Bell, M. A., Eaton, R. H., Dagen, M., Cassidy, M., & Shepherd, J. (1993) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329303000407 · Cited by 13
Prediction of cardiovascular risk. Hypothesis of program is flawed.
Zambanini, A., Smith, M. R., & Feher, M. D. (1999) · PubMed · Cited by 9
Prediction of cardiovascular risk
Zambanini, A., Smith, M., Feher, M. D., Gueyffier, F., Boissel, J., Hingorani, A. D., & Vallance, P. J. (1999) · BMJ · doi:10.1136/bmj.318.7195.1418 · Cited by 9
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
“This excess risk of diabetic persons is in part explained by ‘diabetes-related’ factors, such as type and duration of diabetes, glycaemic control, and presence of retinopathy or microalbuminuria or proteinuria.(53)”
BackgroundMethodCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Metadata
- Authors
- STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M.
- Affiliations
- University of Oxford (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2001-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 671
- ISSN
- 0143-5221 (ISSN-L)
- OpenAlex
- W2117191092
- Cited by
- 1,084
- References
- 51
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 33 · 2022: 44 · 2021: 60 · 2020: 46 · 2019: 42 · 2018: 47 · 2017: 42 · 2016: 39 · 2015: 60 · 2014: 66 · 2013: 68 · 2012: 59
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- coronary artery disease, type 2 diabetes, cardiovascular risk prediction, risk prediction model, glycemia, systolic blood pressure, serum lipids, primary prevention, smoking, sex differences
- MeSH terms
- Adult, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.